Adocia Halts Work on Diabetic Foot Ulcer Candidate After Phase 3 Flop

Adocia is calling it quits for its diabetic foot ulcer candidate BioChaperone PDGF after the candidate failed to meet its primary endpoint in a Phase 3 trial.

The candidate did not improve wound closure over placebo after 20 weeks of treatment in a double-blind, randomized study that enrolled 252 patients, the company said. Study participants received treatment the twice a week.

Adocia said it will stop the development of the candidate to focus on its injectable diabetes therapies. The company does, however, intend to further analyze the data of the trial.